Illumina Inc (ILMN) Maintains Buy Rating

Goldman Sachs published its research report on Illumina Inc ILMN this morning in which they maintain a Buy rating. Analysts note a lack of "material changes" as to why there are no changes in the investment thesis, rating, or price target. Goldman Sachs set the price target at $65.00. Illumina Inc closed Monday at $57.18.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman SachsHealth CareIllumina Inc.Life Sciences Tools & Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!